SCHEDULE: Panacea Venture Reduces Stake in Atara Biotherapeutics
Schedule 13D Amendment
Panacea Venture Healthcare Fund II, L.P. sold 313,446 shares of Atara Biotherapeutics common stock on May 7, 2026.
Summary
- Panacea Venture Healthcare Fund II, L.P. disposed of 313,446 shares of Atara Biotherapeutics, Inc. common stock.
- The shares were sold in open market transactions at a weighted average price of $10.0975 per share.
- Following the transaction, the reporting persons maintain a collective beneficial ownership of 1,318,894 shares, representing approximately 16.1% of the outstanding common stock.
- The filing serves as Amendment No. 3 to the original Schedule 13D filed on May 21, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be perceived negatively, the reporting group retains a significant 16.1% ownership stake.
Positives
- The reporting entity maintains a significant 16.1% stake in the company, signaling continued, albeit reduced, investment interest.
Negatives
- The sale of 313,446 shares represents a reduction in the position held by a major institutional investor.
Risks
- Large-scale selling by significant shareholders can exert downward pressure on the company's share price.
Future Outlook
No specific forward-looking guidance regarding the company's operations or future investment intentions was provided in this filing.
Industry Context
StockSavvy.ai notes that institutional divestment in the biotech sector is often driven by portfolio rebalancing or fund lifecycle requirements rather than a negative outlook on the specific issuer's clinical pipeline.
Comparison to Industry Standards
- The 16.1% remaining stake remains a substantial position for a venture capital firm, consistent with long-term holding strategies in the biotechnology sector.
Stakeholder Impact
- Shareholders may experience short-term volatility due to the volume of shares sold in the open market.
Next Steps
- Reporting persons will continue to monitor their investment in Atara Biotherapeutics.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Original Schedule 13D filing date. |
| 03/10/2026 | Date of outstanding share count disclosure. |
| 04/24/2026 | Date of Issuer's Definitive Proxy Statement. |
| 05/07/2026 | Date of the share sale transaction. |
| 05/11/2026 | Filing date of Amendment No. 3. |
Keywords
Atara Biotherapeutics, ATRA, Schedule 13D, Panacea Venture, Insider Selling, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.